68Ga-LNC-1007

N/A

Report date: 2026/01/21 20:00:47
NME

Base Information

Drug Name68Ga-LNC-1007
Drug Alias Name68Ga-FAPI-RGD68Ga-LNC-1007
ClassificationRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Nuclides > Gallium > 68GaRadiation-emitting products > Radionuclide Drug Conjugates +[4] 
Mechanisms of ActionIntegrin alpha-V/beta-3 antagonistsFibroblast activation protein alpha antagonistsPositron-emission tomography enhancers
TargetsIntegrin alpha-V/beta-3Prolyl endopeptidase FAP
Therapy Area/IndicationsCarcinoma, Renal CellNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySingaporeMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesYantai Lannacheng Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesPeking Union Medical College HospitalFujian Medical UniversityYantai Lannacheng Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Renal CellNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A